<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">BETAXOLOL HYDROCHLORIDE</span><br/>(be-tax'oh-lol)<br/><span class="topboxtradename">Betoptic, </span><span class="topboxtradename">Betoptic-S, </span><span class="topboxtradename">Kerlone<br/></span><b>Classifications:</b> <span class="classification">eye preparation</span>; <span class="classification">miotic (antiglaucoma agent)</span>; <span class="classification">autonomic nervous system agent</span>; <span class="classification">beta-adrenergic blocker</span><br/><b>Prototype: </b>Propranolol<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>10 mg, 20 mg tablets; 0.25%, 0.5% ophthalmic solution</p>
<h1><a name="action">Actions</a></h1>
<p>Acts as a beta<sub>1</sub>-selective adrenergic receptor blocking agent, especially in the cardioselective beta<sub>1</sub> receptors. Its antihypertensive effect is thought to be due to: (1) decreasing cardiac output, (2) reducing sympathetic nervous
         system outflow to the periphery resulting in vasodilatation, and (3) suppression of renin activity in the kidney.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>All three mechanisms result in its antihypertensive effect.</p>
<h1><a name="uses">Uses</a></h1>
<p>Hypertension. Ocular use for intraocular hypertension, chronic open angle glaucoma (<b>see Appendix A-1</b>).
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Sinus bradycardia, AV block greater than first degree, cardiogenic shock, glaucoma, angle closure (unless with a miotic).
         Safety during pregnancy (category C) and in children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Concomitant use of systemic beta-adrenergic blocking agents; history of heart failure; diabetes mellitus; with evidence of
         airflow obstruction or reactive airway disease; lactation.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hypertension</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 510 mg q.d. (max: 20 mg/d in 12 divided doses)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Check pulse before administering betaxolol, oral or ophthalmic. If there are extremes (rate or rhythm), withhold medication
            and call the physician.
         </li>
<li>Be aware tablet may be crushed before administration and taken with fluid of patient's choice.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CV:</span> Bradycardia, hypotension. <span class="typehead">CNS:</span> Depression. <span class="typehead"> Respiratory:</span> Increased airway resistance. <span class="typehead">Special Senses:</span> With ophthalmic solution, <span class="speceff-common">mild ocular stinging</span> and discomfort, tearing. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Reserpine</b> and other <span class="classification">catecholamine-depleting agents</span> may cause additive hypotensive effects or bradycardia. <b>Verapamil</b> may cause additive heart block. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 90% of PO dose reaches systemic circulation. <span class="typehead">Onset:</span> 0.51 h. <span class="typehead">Peak:</span> 2 h. <span class="typehead">Duration:</span> &gt;12 h. <span class="typehead">Metabolism:</span> Metabolized in liver to at least 5 metabolites. <span class="typehead">Elimination:</span> 3040% excreted in urine, 5060% excreted in bile and feces. <span class="typehead">Half-Life:</span> 34 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor pulse rate and BP at regular intervals in patients with severe heart disease.</li>
<li>Monitor therapeutic effectiveness. Some patients develop tolerance during long-term therapy.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report unusual pulse rate or significant changes to physician according to parameters provided.</li>
<li>Adhere to regimen <small>EXACTLY</small> as prescribed. Do not stop drug abruptly; angina may be exacerbated; dosage is reduced over a period of 12 wk.
         </li>
<li>Report difficulty in breathing promptly to physician. Drug withdrawal may be indicated.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>